MIB-626 is under clinical development by Metro International Biotech and currently in Phase II for Friedreich Ataxia. According to GlobalData, Phase II drugs for Friedreich Ataxia have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MIB-626’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MIB-626 overview
MIB-626 is under development for the treatment of Friedreich’s ataxia (FA), coronavirus disease 2019 (COVID-19), acute renal failure (ARF) (acute kidney injury), mild dementia and Leber’s hereditary optic neuropathy. The drug candidate is a crystallized precursor of nicotinamide adenine dinucleotide (NAD+). It is administered through oral route.
It was also under development for the treatment of muscle endurance (musculoskeletal disorders) and mitochondrial myopathy.
Metro International Biotech overview
Metro International Biotech is a clinical-stage drug development company that develops nicotinamide adenine dinucleotide (NAD+) cellular protection mechanisms focusing on mitochondrial diseases. The company also offers a solid oral dosage formulation of MIB-626. Metro International Biotech’s NAD+ serves in therapeutic areas for various aging and numerous diseases such as mitochondrial dysfunction, inflammation, and other related diseases. The company operates in the US. Metro International Biotech is headquartered in Worcester, Michigan, the US
For a complete picture of MIB-626’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
